home | publications


1. Androgen dependent oncogenic activation of ETS transcription factors by recurrent gene fusions in prostate cancer: Biological and Clinical Implications
Dobi A, Sreenath T, Srivastava S.
(Book chapter). Androgen-Responsive Genes in Prostate Cancer (Edited by Zhou Wang), Springer Edition, New York USA 2013.

2. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence
Zhang C, Kallakury BV, Ross JS, Mewani RR, Sheehan CE, Sakabe I, Luta G, Kumar D, Yadavalli S, Starr J, Sreenath TL, Srivastava S, Pollard HB, Eidelman O, Srivastava M, Kasid UN.
Int J Cancer. 2013; 133:31-42.

3. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.
Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, Srivastava S, Nelson PS, Porter CR.
The Prostate. 2013; 73:905-12.

4. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.
Szász AM, Nyirády P, Majoros A, Székely E, Rosen P, Srivastava S, Dobi A, Szendrõi A, Kulka J, Romics I.
International Urology and Nephrology. 2013; 45:727-733.

5. Low frequency of ERG oncogene alterations in prostate cancer patients from India.
Rawal S, Young D, Williams M, Colombo M, Krishnappa R, Petrovics G, McLeod DG,Srivastava S, Sesterhenn IA.
Journal of Cancer. 2013; 4:468-472.

6. miR-30 Connects Src to EMT and ERG.
Kao C-J, Martinez A, Shi X-B, Dobi A, deVere White RW, Kung H-J.
Oncogene. 2013 Jun [Epub ahead of print].

7. Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.
Farrell J, Petrovics G, McLeod DG, Srivastava S.
International Journal of Molecular Sciences. 2013; 14(8):15510-31.

8. TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair.
Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, MilosevicM, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.
Clin Cancer Res. 2013 Sep [Epub ahead of print].

9. Health-related quality of life for men with prostate cancer – an evaluation of outcomes 12-24 months after treatment.
Brassell SA, Elsamanoudi SI, Cullen J, Williams ME, McLeod DG.
Urol Oncol. 2013; 31:1504-10.

10. Anterior Tumors of the Prostate: Clinicopathologic Features and Outcomes.
Mygatt J, Sesterhenn IA, Rosner I, Chen Y, Cullen J, Morris-Gore T, Barton J, Dobi A, Srivastava S, McLeod DG, Brassell S.
Prostate Cancer and Prostatic Diseases. In press (2013).

11. Evaluation of ERG Responsive Proteome in Prostate Cancer.
Tan S-H, Furusato B, Fang XP, Fang H, Mohamed AA, Griner N, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, Sesterhenn IA, Saxena S and Srivastava S.
Prostate. 2013 Sep [Epub ahead of print].